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Summary  
There is a pressing need to develop novel antibacterial agents given the widespread antibiotic 
resistance among pathogenic bacteria and the low specificity of the drugs available. Endolysins 
are antibacterial proteins that are produced by bacteriophage-infected cells to digest the 
bacterial cell wall for phage progeny release at the end of the lytic cycle. These highly efficient 
enzymes show a considerable degree of specificity for the target bacterium of the phage. 
Furthermore, the emergence of resistance against endolysins appears to be rare as the enzymes 
have evolved to target molecules in the cell wall that are essential for bacterial viability. Taken 
together, these factors make recombinant endolysins promising novel antibacterial agents. The 
chloroplast of the green unicellular alga Chlamydomonas reinhardtii represents an attractive 
platform for production of therapeutic proteins in general, not least due to the availability of 
established techniques for foreign gene expression, a lack of endotoxins or potentially infectious 
agents in the algal host, and low cost of cultivation. The chloroplast is particularly well suited to 
the production of endolysins as it mimics the native bacterial expression environment of these 
proteins while being devoid of their cell wall target. In this study the endolysins Cpl-1 and Pal, 
specific to the major human pathogen Streptococcus pneumoniae, were produced in the C. 
reinhardtii chloroplast. The antibacterial activity of cell lysates and the isolated endolysins was 
demonstrated against different serotypes of S. pneumoniae, including clinical isolates and total 
recombinant protein yield was quantified at ~1.3 mg/g algal dry weight. 
 
Introduction 
The increase of antibiotic resistance in the last few decades has severely reduced the reliability 
of antibiotic treatments (Levy 2005). In particular, the prevalence and range of multi-drug 
resistant strains has increased alarmingly (Levy and Marshall 2004; WHO report 2014), and 
there has been a simultaneous decline in the development of new antibiotics, mainly owing to 
the lower profitability of antibiotics compared to other drugs (Spellberg et al. 2008; Wright 
2012). Health agencies, including the World Health Organization (WHO) and the Infectious 
Disease Society of America (IDSA) have warned that antimicrobial resistance is an “increasingly 
serious threat to global public health” and that there is a real risk of falling back into a pre-
antibiotic era in the 21st century (Infectious Diseases Society of America (IDSA) 2011; WHO 
report 2014). Furthermore, many antibiotics are broad spectrum and therefore each treatment 
affects the human commensal bacterial flora in addition to the target pathogen. Not only does 
this increase the patient’s susceptibility to opportunistic bacterial and fungal pathogens, but 
there is also increasing evidence that disruption to the natural microbiota can play a key role in 
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conditions such as obesity, type 1 diabetes, inflammatory bowel disease, allergies, and asthma 
(Chen and Blaser 2007; Blaser 2011).  Repeated exposure to broad spectrum antibiotics can 
also result in the spread of antimicrobial resistance genes within the human microbiome, which 
in turn can be passed on to pathogenic bacteria (Schmelcher et al. 2012). With the availability of 
enhanced diagnostic methods, it would therefore be highly desirable to develop narrow 
spectrum antibiotics that specifically target the pathogen, thus reducing the collateral effects on 
the commensal bacterial flora, and in turn the spread of antimicrobial resistance genes (Blaser 
2011).  
Endolysins are bacteriophage-encoded enzymes that accumulate in the cytoplasm of infected 
bacterial cells throughout the lytic cycle (Loessner 2005). Towards the end of this cycle the next 
generation of phage particles are assembled, and the synthesis of a second phage protein known 
as a holin is initiated. These holins create pores in the plasma membrane allowing the endolysin 
to exit the cytoplasm and attack the cell wall of the infected bacterium (Young et al. 2000; 
Schmelcher et al. 2012). Cleavage of specific bonds within the peptidoglycan results in the lysis 
of the host cell and the release of the phage progeny (Loessner 2005). In the case of Gram-
positive bacteria, where the peptidoglycan layer is open to the bulk solution, such enzymes have 
been shown to function as ‘exo-lysins’, lysing the target bacterium when applied externally 
(Schmelcher et al. 2012). Gram-positive targeting endolysins are also typically highly specific 
for the cell wall of the bacterial species from which they are naturally produced (Borysowski et 
al. 2006), which allows for their use as targeted antibacterial treatments that specifically 
eliminate the pathogen without harming the commensal human microbiota, in contrast to many 
conventional antibiotics. 
 
Bacteriophages and their host bacterial strains have co-evolved over billions of years, with the 
functionality of the phage endolysin representing a key factor in the ensuing arms race: if a host 
strains develops effective resistance against endolytic attack then the phage progeny will not be 
released, and that particular phage lineage will not continue. It is thus inferred that any 
modern-day phage must necessarily have evolved to target components in the cell wall that are 
essential for bacterial viability, and as such are highly immutable. It was proposed that the 
development of bacterial resistance against an endolysin-based antibiotic would be less 
frequent than that seen for conventional antibiotics (Schmelcher et al. 2012), and indeed 
attempts to induce resistance by treating bacterial populations to sub-lethal doses of endolysin 
over several generations (even in combination with a mutagen) have failed to generate any 
observable effect (Loeffler et al. 2001; Schuch et al. 2002). Recombinant endolysins have been 
successfully tested against several different pathogenic bacteria in vitro and in a range of animal 
models (Loeffler et al. 2001; Schuch et al. 2002; Entenza et al. 2005). The high activity, 
specificity, and low occurrence of resistance make endolysins highly promising candidates for 
use as novel antibacterial agents in human and veterinary medicine.  
 
Despite the benefits associated with endolysins, they are yet to achieved clinical adoption. The 
reason for this is largely considered to be economic; the production costs for recombinant 
therapeutic proteins are significantly higher than small molecule bioactives such as traditional 
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antibiotics (Dove 2002). It is therefore desirable to develop an inexpensive production system 
for recombinant endolysins that also fulfils all safety criteria for the production of therapeutic 
proteins. Microalgae offer several potential advantages for the production of recombinant 
proteins over more established expression platforms, including a low cost of cultivation using 
media with simple nutrient requirements and the ability to rapidly develop and scale-up 
production. A number of key species have also been granted GRAS (Generally Recognised as 
Safe) status for human consumption – as such, the removal of any endogenous toxins and 
infectious agents from the product is not a concern (Dove 2002; Rasala et al. 2010; Specht et al. 
2010). Furthermore, the ability of photosynthetic organisms to grow using just light, inorganic 
substances and CO2 has the potential to decrease the overall carbon footprint of the production 
process. Finally, microalgae can be grown in full containment under sterile conditions in simple 
photobioreactors (PBRs) (Specht et al. 2010; Gimpel et al. 2014), significantly reducing the 
potential for release of transgenes to the environment and reducing the risk of environmental 
contamination of the production system. 
The eukaryotic microalga Chlamydomonas reinhardtii offers all the aforementioned advantages 
together with established techniques for the expression of foreign genes from the chloroplast 
and nuclear genomes (Fuhrmann et al. 1999; Almaraz-Delgado et al. 2014). Expression in the 
chloroplast is more attractive since the integration of transgenes into the genome occurs via 
homologous recombination and so the insertion site can be easily defined. In addition, the levels 
of recombinant proteins that can be achieved in the organelle are markedly higher compared to 
expression from the nuclear genome (Potvin and Zhang 2010). Furthermore, the chloroplast 
compartment offers several specific advantages for the production of endolysins given its 
evolution from a cyanobacterial endosymbiotic ancestor, and hence its similarity to the 
bacterial cells in which endolysins naturally accumulate. For example, (i) recombinant proteins 
are retained and accumulate exclusively within the chloroplast (Tran et al. 2013), but the 
chloroplast lacks a peptidoglycan cell wall to which the endolysin might bind or cleave during 
cell breakage, thereby hindering cultivation and purification;  (ii) endolysins are likely to have a 
long-half life in this environment since the endogenous proteases in the chloroplast are 
homologues to the bacterial proteases to which endolysins have evolved to be resistant (Adam 
et al. 2006); (iii) proteins synthesised in the chloroplast are not subject to post-translational 
modifications such as glycosylation, unlike cytoplasmic eukaryotic production platforms. 
Indeed, the potential exploitation of chloroplasts of plants and microalgae as platforms for the 
production of therapeutic proteins such as anti-microbials and vaccines has been highlighted in 
several recent reviews (Bock and Warzecha 2010, Bock 2015, Daniell et al. 2016, Rasala and 
Mayfield 2015).  
The biosynthesis of active endolysins in the chloroplast of tobacco was demonstrated by Oey et 
al. (2009a) who showed that the PlyGBS endolysin, which targets Streptococcus pathogens, can 
accumulate in the leaves to levels as high as 70% of total soluble protein. A second study by the 
same group similarly showed high level production in tobacco of two further Streptococcus 
endolysins, Pal and Cpl-1 (Oey et al. 2009b). Additionally, this study highlighted the limitations 
of trying to over-express endolysin genes using an E. coli platform, since both of Pal and Cpl-1 
had a lethal effect on the bacterium, potentially caused by unspecific peptidoglycan cleavage at 
high concentrations or by binding to the cell wall (Oey et al. 2009b). The tobacco chloroplast has 
also been employed to make other types of antimicrobial proteins and peptides that are 
technically difficult to produce in established platforms. For example, the clinically relevant 
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antimicrobial peptides retrocyclin and protegrin have complex secondary structures with 
multiple disulphide bonds, but are able to assemble into a functional form in the chloroplast 
(Lee et al., 2010). However, there are major challenges associated with the commercial 
production of recombinant pharmaceuticals in plants grown in fields or greenhouses, as 
compared to single cells cultured in contained, sterile fermenter-based systems. These 
challenges include both compliance with good manufacturing practice (GMP) regulations, and 
the potentially high cost of purifying product from plant biomass under these GMP regulations 
(Fischer et al. 2012).  
In this study we have investigated the production of endolysins in the chloroplast of C. 
reinhardtii to examine the suitability of this microalga as a production platform. We have 
focussed on the Cpl-1 and Pal endolysins which are specific to the human pathogen 
Streptococcus pneumoniae, since previous studies have demonstrated the antibacterial efficacy 
of these endolysins both in vitro and in vivo (Garcia et al. 1983a; Loeffler et al. 2001; Jado et al. 
2003; Grandgirard et al. 2008). We report the generation of transgenic C. reinhardtii lines 
expressing codon-optimised genes for Pal and Cpl-1, and the stable accumulation of the 
endolysins to a level of ~1% of total soluble protein (TSP). Both crude cell lysates and the 
isolated endolysins show antibacterial activity against S. pneumoniae, including clinical isolates 
with resistance against penicillin and co-trimoxazole. 
 
Results 
Creation of marker-less transgenic lines of Chlamydomonas reinhardtii expressing pal 
and cpl-1 in the chloroplast 
To investigate the synthesis of endolysins in C. reinhardtii, we created transgenic lines in which 
a synthetic gene encoding either Pal or Cpl-1 was introduced into the chloroplast genome. The 
coding regions of the genes were designed based on the codon preference for C. reinhardtii 
chloroplast genes and synthesized de novo. (Nakamura et al. 2000) (Figure S1). The coding 
sequence for a C-terminal human influenza haemagglutinin (HA) epitope tag was also added to 
each gene to facilitate the detection of the proteins. These synthetic genes are referred to as pal 
and cpl-1. A pal gene without the HA-tag sequence (referred to as pal(HA-)) was also included to 
investigate whether the HA-tag has an influence on the stability or activity of the endolysin. As 
shown in Figure 1a, the genes were cloned into the chloroplast transformation vector pSRSapI 
that uses the chloroplast psaA-1 promoter and 5’ untranslated region (UTR) to drive transgene 
expression (Young and Purton 2014). In order to compare the efficiency of expression, pal and 
cpl-1 were also cloned into a second vector, pASapI, that differs from pSRSapI in that it uses the 
promoter/5’UTR from the atpA chloroplast gene (Economou et al. 2014). Each vector is 
designed to target the transgene cassette to a neutral site in the chloroplast genome 
downstream of the essential photosystem II gene psbH, with restoration of phototrophy in the 
ΔpsbH recipient line TN72 used for selection of transformants (Young and Purton 2014). Such 
transformants therefore lack any antibiotic-resistance marker and carry the gene of interest 
(GOI) as the only section of foreign DNA (Figure 1a).  
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We analysed colonies of putative C. reinhardtii transformants for the correct insertion of the 
endolysin genes into the chloroplast genome and homoplasmicity of the polyploid genome using 
a 3-primer PCR assay (Economou et al. 2014). As shown in Figure 1b, homoplasmic 
transformants were obtained for pSRSapI_cpl-1, _pal and _pal(HA-). Homoplasmic 
transformants were also obtained for the pASapI_pal and pASapI_cpl-1 constructs, and also for a 
control transformant line (TN72_control) lacking the GOI in which TN72 was transformed with 
the empty pSRSapI vector (data not shown). Furthermore, the correct insertion of the 
expression cassettes carrying pal and cpl-1 into the lines TN72_pal and Tn72_cpl-1 was 
confirmed by Southern blot analysis using probes binding within the pal and cpl-1 genes, as well 
as a probe that binds adjacent to the insertion site of the expression cassette (Figure S2).  
 
Accumulation of Pal and Cpl-1 in the C. reinhardtii chloroplast 
We analysed representative TN72_cpl-1 and TN72_pal lines generated using the pSRSapI 
constructs for the presence of the recombinant protein. This was carried out on crude cell 
extracts by western blot analysis using antibodies against the HA-tag. The Cpl-1 protein has an 
expected size of 40 kDa and Pal an expected size of 36 kDa, and as seen in Figure 2a, both 
proteins are readily detected in the extracts, confirming the accumulation of Pal and Cpl-1 in the 
respective lines. For the detection of untagged Pal, antibodies to Pal were raised in rabbits using 
two synthetic peptides derived from the protein sequence (Figure S3) and used to compare Pal 
levels in the TN72_pal and TN72_pal(HA-) lines. As seen in Figure 2b, a 36 kDa band of similar 
intensity is seen for both the HA-tagged and untagged protein indicating that the HA-tag does 
not interfere with the stability of this endolysin. Furthermore, we did not observe any reduction 
in growth rate or biomass production of the Pal and Cpl-1 producing strains in comparison to 
TN72_control, indicating that the production of the endolysins in the chloroplast is not 
detrimental to C. reinhardtii growth (shown for TN72_pal in Figure S4).  
 
When we compared the levels of Pal and Cpl-1 synthesized using the atpA promoter/5’UTR with 
those from the psaA-1 promoter/5’UTR, a higher level was seen for both proteins when using 
the psaA-1 elements (Figures S5 and S6), as has been reported previously (Michelet et al. 2011). 
We therefore used the transgenic lines with the psaA-1 promoter/5’UTR for all further studies. 
 
To investigate the stability of the endolyins in the C. reinhardtii chloroplast, we grew cultures of 
TN72_pal to mid-log phase and specifically inhibited further protein synthesis in the chloroplast 
with the addition of chloramphenicol. As shown in Figure 3, there is very little decrease in the 
amount of Pal in the chloramphenicol-treated cultures compared to the untreated controls even 
after 71 hours, and the protein was still detectable 122 hours after the start of the inhibition. In 
contrast, the endogenous D1 protein (a component of photosystem II) decreased to 
undetectable levels seven hours after the start of the inhibition. In addition, we found that the 
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stability of Pal was further increased during cultivation in the dark (Figure 3). This indicates a 
high stability of Pal in the C. reinhardtii chloroplast, as has been reported previously for both Pal 
and Cpl-1 when produced in the tobacco chloroplast (Oey et al. 2009b). 
 
Isolation and quantification of Pal and Cpl-1 
For the development of the C. reinhardtii chloroplast as a production platform for therapeutic 
endolysins, it is important to show that the proteins can be extracted and purified in a 
biologically active state. Furthermore, it was necessary to produce pure standards for the 
quantification of Pal and Cpl-1 levels within the algal cell. We isolated the endolysins from crude 
cell extracts as described in the methods, using ultracentrifugation followed by chromatography 
with the weak anion exchanger diethylaminoethyl (DEAE) cellulose and choline as specific 
eluent. Pal and Cpl-1 bind to choline in the S. pneumoniae cell wall, and DEAE is a choline 
analogue which is commonly used for the affinity chromatography of choline binding proteins 
(Sanz et al. 1988; Jado et al. 2003). As the final step, we concentrated Pal and Cpl-1 by either 
ammonium sulphate precipitation or with centrifugal concentrators. As seen in Figure 4, the Pal 
and Cpl-1 isolated from the algal biomass using this procedure is in a near purified state with 
only trace amounts of other proteins, including a 55 kDa protein which is most likely the large 
subunit of the highly abundant Rubisco enzyme.  
In order to optimize the yield of recombinant endolysin, we first analysed the level of Pal in the 
algal cell at different growth stages and conditions. This indicated that under mixotrophic 
growth conditions the concentration of Pal on a per cell basis is highest during the logarithmic 
phase and then declines once the cells enter stationary phase (Figure S5, S7 and S8). However, 
different experiments suggested that a shift from light to dark (i.e. heterotrophic) can limit this 
decline (Figure S7 and Figure 3), possibly due to the inactivity of chloroplast proteases that are 
dependent on ATP generated through photo-phosphorylation as reported by Preiss et al. 
(2001). However, heterotrophic cultivation of the transformant line from the start of 
inoculation resulted in an overall reduction in Pal yield per culture volume because of a 
reduction in cell density under these conditions when compared to mixotrophic growth (Figure 
S8). Hence, the maximal yield per culture volume was achieved towards the end of the 
logarithmic phase under conditions of mixotrophic growth in this study.  
 
To quantitate the amount of recombinant protein, we performed western blot analyses with a 
dilution series of the isolated endolysins alongside crude cell lysates of TN72_pal and TN72_cpl-
1 taken from mid- and late-logarithmic phase cultures (Figure 5a). Using the Odyssey® imaging 
system (LI-COR) to quantify the amount of antigen in the samples (Figure 5b), we found that 
both Pal and Cpl-1 represent ~1 % of total soluble protein (TSP) in C. reinhardtii. This equates 
to ~1 mg of recombinant protein per litre of culture volume at the end of the logarithmic phase 
during mixotrophic cultivation, or ~1.3 mg per gram of algal dry weight (Table 1). 
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Antibacterial activity of Pal and Cpl-1  
To analyse whether Pal and Cpl-1 produced in the C. reinhardtii chloroplast are biologically 
active, we performed turbidity reduction assays (TRA) with the target bacterium Streptococcus 
pneumoniae. In a TRA, the lytic activity of an enzyme is measured as a decrease in optical 
density (OD595) of a bacterial suspension. Deoxycholate, which induces rapid autolysis of S. 
pneumoniae, was used as a positive control (Mellroth et al. 2012). As seen in Figure 6, after the 
addition of a crude extract from TN72_pal or TN72_cpl-1, the OD595 of a S. pneumoniae 
suspension decreased in comparison to assays with crude extract from TN72_control or 
untreated controls. In control assays the OD595 decreased slightly as well, which is most likely 
caused by autolysis of S. pneumoniae. This indicates that Pal and Cpl-1 produced in C. reinhardtii 
are biologically active and able to lyse S. pneumoniae cells. The lytic activity of Pal and Cpl-1 was 
confirmed in more than 10 independent TRAs. Crude extracts containing either HA-tagged or 
untagged Pal caused comparable rates of lysis and decreased the OD595 to a similar extent in five 
independent TRAs. This suggests that the HA-tag does not interfere with the enzymatic activity 
of the endolysin. Furthermore, we found that the extracts containing Pal and Cpl-1 were active 
against different clinical isolates of S. pneumoniae, with all four serotypes (6A, 6B, 6C and 19F) 
showing lysis including strain ST4157 that is intermediate resistant to penicillin (MIC (Minimal 
inhibitory concentration): 0.125 µg/ml) and resistant to co-trimoxazole (MIC: 6 µg/ml) (Figure 
7a and S9). The specificity of Pal was demonstrated by performing TRAs using Escherichia coli, 
Staphylococcus aureus and Streptococcus pyogenes. As shown in Figure 7b and S10, the algal 
extract containing Pal, which was active against S. pneumoniae cells, did not have a measurable 
effect on the tested bacteria. This suggests that the algal-produced Pal shows specificity for S. 
pneumoniae as described for bacteria-produced Pal and other endolysins specific to Gram-
positive bacteria (Loeffler et al. 2001; Schmelcher et al. 2012). 
To demonstrate directly that Pal and Cpl-1 kill S. pneumoniae, we determined the number of 
colony-forming units per ml (cfu/ml) remaining in a cell suspension after endolysin treatment 
(Figure 8). One complication we encountered in initial experiments using the crude algal 
extracts was the presence of an endogenous bactericidal activity in C. reinhardtii, as has been 
previously reported (Jørgensen 1962; Ghasemi et al. 2007). While this activity did not cause cell 
lysis (see the TN72_control in Figure 6) it did have a marked effect on the viability of S. 
pneumoniae and therefore masked the effect of the endolysins in the titre assay (data not 
shown). In order to demonstrate the killing of S. pneumoniae by Pal and Cpl-1 without the 
interference of this activity, we repeated the assays with the isolated protein. The addition of 25 
µg/ml of Pal or 20 µg/ml Cpl-1 reduced the bacterial titre of strain 16 NP3 by nearly 4 log10 
units (Pal: 3.8 ± 0.5 and Cpl-1: 3.9 ± 0.2 Δlog10 cfu/ml) in comparison to an untreated control. 
Treatment of S. pneumoniae D39 with 22.5 µg/ml of Pal reduced the cfu/ml by 3.6 ± 0.3 log10 
units. A treatment with 45 µg/ml of Pal was sufficient to kill all S. pneumoniae cells in 
suspensions of D39 and 16 NP3, which was a reduction by more than 7 log10 units for both 
strains. This supports the TRA results that the recombinant Pal and Cpl-1 are able to effectively 
kill S. pneumoniae through cell lysis. Furthermore, it shows that the two endolysins retain 
antibacterial activity during the purification procedure.  
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Discussion 
In this study, we investigated the synthesis of two bacteriophage endolysins specific to the 
human pathogen S. pneumoniae in the chloroplast of C. reinhardtii. We found that Pal and Cpl-1 
accumulate as predominately full-length proteins in the transgenic lines. Furthermore, for Pal 
we demonstrated that this endolysin is highly stable despite the presence of a suite of proteases 
within the algal chloroplast (Adam et al. 2006). The antibacterial activity of Pal and Cpl-1 
against different serotypes of S. pneumoniae, including clinical isolates, was demonstrated using 
both cell lysates and the isolated proteins. Incubation with 25 µg/ml Pal or 20 µg/ml Cpl-1 
resulted in a decrease in colony forming units (cfu) for S. pneumoniae of nearly four log10 units. 
These activities are similar to the antibacterial activities and minimal inhibitory concentrations 
(MIC) described for Pal and Cpl-1 synthesized in E. coli or tobacco (Loeffler et al. 2001; Loeffler 
and Fischetti 2003; Rodríguez-Cerrato et al. 2007; Oey et al. 2009b), which suggests that Pal and 
Cpl-1 are produced in a predominately active form in the algal chloroplast. 
 
The production of the endolysins did not have any negative impact on the viability of the alga 
suggesting that the production in C. reinhardtii could be performed using continuous cultivation 
systems. Both proteins account for approximately 1% of total soluble protein (TSP) during 
mixotrophic cultivation, which equates to ~1.3 mg of recombinant endolysin per gram of cell 
dry weight. These yields are similar to previous reports on the production of recombinant 
proteins in the C. reinhardtii chloroplast, which range from 0.1% to 5% of TSP (Sun et al. 2003; 
He et al. 2007; Manuell et al. 2007; Dreesen et al. 2010; Rasala et al. 2010; Tran et al. 2013), 
although significantly lower than yields reported for tobacco chloroplasts which are typically 
10–30% of the TSP in leaves, and in extreme cases are as much as 70% (Bock 2015). The reason 
for this difference is not clear, but might reflect the much tighter anterograde regulation of 
chloroplast gene expression by the numerous nuclear-encoded factors in the single chloroplast 
of the algal cell (Lefebvre-Legendre et al. 2015, Douchi et al. 2016). Many of these factors act on 
the 5’UTR of specific gene transcripts and are required for RNA stability or translation 
initiation; they therefore also regulate transgenes driven from the same 5’UTR. Competition 
between endogenous and foreign transcripts with the same 5’UTR for low abundance factors 
might therefore limit the level of recombinant protein.  Indeed, higher yields were achieved by 
using the psbA promoter/5’UTR to drive transgene expression in a psbA deletion mutant (Rasala 
et al. 2010; Manuell et al. 2007). However, the generation of non-photosynthetic transgenic 
lines negates the key value of the alga as a light-driven cell factory; we have therefore focused 
on maximising endolysin production in a photosynthetic line. Further studies of the 
mechanisms of anterograde regulation in the C. reinhardtii chloroplast combined with the 
redesign of UTR elements to eliminate regulatory elements (Specht and Mayfield 2013) should 
result in significant improvements in protein production levels (Rasala and Mayfield 2015).  
 
Microalgae are gaining increasing attention as alternative expression platforms due to the 
simple and cheap nutrient/cultivation requirements, as well as easy and cost-effective 
scalability, which will potentially result in low production costs for recombinant proteins 
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(Barrera and Mayfield 2013; Gimpel et al. 2014). Furthermore, the GRAS status of several green 
algal species including C. reinhardtii, which lack endotoxins and infectious agents, might 
decrease downstream processing costs and enables the use of dried algal biomass for the 
administration of therapeutics and vaccines (Dreesen et al. 2010; Gregory et al. 2012). However, 
C. reinhardtii cultures reach lower final cell densities and have lower recombinant protein yields 
than conventional expression systems such as mammalian cells, yeast or bacterial systems 
(Andersen and Krummen 2002; Jørgensen et al. 2014). Therefore, to determine whether the C. 
reinhardtii chloroplast has the potential to be cost-competitive with conventional expression 
platforms, an accurate costing for the production of recombinant proteins at scale in C. 
reinhardtii needs to be generated.  
 
This study represents a first report and “proof of concept” for the production of endolysins in 
the C. reinhardtii chloroplast. The use of endolysins as antibacterial agents is a relatively new, 
but potentially immense field. It is estimated that, in total, 1031 bacteriophages exists globally 
(Abedon 2008), so there is a huge untapped resource of endolysins that could be investigated 
for their potential use as antimicrobials in a wide range of applications (Borysowski et al. 2006). 
A recent study even describes an endolysin that can traverse epithelial membranes and 
eliminate intracellular Streptococcus pyogenes cells (Shen et al.  2016). Additionally, several 
research groups have started to create designer endolyins by removing cell wall binding 
domains, adding additional catalytic domains, or combining domains from different endolysins 
(Schmelcher et al. 2012). Furthermore, endolysins combined with polycationic peptides have 
been created that are effective against Gram-negative bacteria. These enzymes are referred to 
as artilysins (Briers et al. 2014). The C. reinhardtii chloroplast might offer advantages especially 
for the production of endolysins and artilysins specific to Gram-negative bacteria. These 
enzymes are less specific and can have adverse effects on bacterial production systems 
containing the peptidoglycan substrate (Oey et al. 2009b; Briers et al. 2014). The successful 
production in the C. reinhardtii chloroplast of a Gram-negative endolysin that cannot be 
produced in bacterial systems would demonstrate a clear advantage of this microalga as an 
expression platform for endolysins. 
Overall it is acknowledged that the field of therapeutic protein production in the green 
microalga C. reinhardtii is in its infancy, and at present is not a viable alternative to more mature 
technologies. That being said, the use of an algal platform does hold a number of intrinsic 
advantages over other systems including cost of cultivation and sustainability. The path to 
greater adoption of this, and similar platforms will likely start with niche applications 
specifically tailored to the unique characteristics exhibited by the algal host; the particular 
suitability of the C. reinhardtii chloroplast for recombinant endolysin expression can be seen as 
a first step on this road. 
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Experimental procedures 
C. reinhardtii strains and growth conditions 
The recipient strain used to create the transformant lines was TN72, a psbH deletion mutant of 
the cell-wall deficient C. reinhardtii strain cw15.mt+ (Wannathong et al. 2016). TN72 was 
maintained on Tris-Acetate-Phosphate (TAP) medium at 20 ºC and 5-10 µmol/m2/s light, as 
were transformant lines following selection on High Salt Minimal (HSM) medium (Harris 2009). 
Liquid cultures were grown in Erlenmeyer flasks at 100 – 200 µmol/m2/s, 120 rpm shaking and 
25 ºC in either illuminated shaking incubators or Algem photobioreactors (Algenuity, 
Stewartby, UK) for growth studies. Growth was measured by recording the optical density at 
750 nm with a Unicam UV/Vis Spectrometer (Thermo Electron Corporation, USA) or 740 nm in 
the Algem photobioreactor. 
 
Bacterial strains and growth conditions 
Activity assays were performed with the S. pneumoniae strain 16 NP3 (serotype 19F) or D39. 
Additional assays were with clinical isolates: ST65 = serotype 6A, H08212 0259; ST176 = 
serotype 6B, H08052 0052; ST1390 = serotype 6C, H05252 0075; ST4157 = serotype 6B, 35 
NP1. The S. pneumoniae strains and S. pyogenes (ATCC 19615, Streptococcus group A) were 
grown on Columbia blood agar plates overnight at 35 ºC under anaerobic or aerobic conditions, 
respectively. Liquid cultures were grown in trypticase soy broth (30 g/L trypticase soy broth, 3 
g/L yeast extract) overnight at 35 ºC without shaking. Anaerobic conditions were generated 
using Oxoid AGS CO2Gen Compact gas packs and an anaerobic jar from Oxoid. S. aureus (ATCC 
28213) liquid cultures were grown in ISO-Sensitest broth from Oxoid overnight at 35 ºC with 
shaking. All target bacteria were obtained from the Royal Free Hospital (London, UK). 
 
Plasmid construction 
Endolysin coding sequences (including a C-terminal human influenza haemagglutinin (HA) tag 
sequence) were codon-optimised for the C. reinhardtii chloroplast to a Codon Adaption Index 
(CAI) of 0.8 using the Kazusa CAI table (Nakamura et al. 2000) and synthesized de novo by 
GENEART (Regensburg, Germany). A 5’ SapI and a 3’ SphI restriction site was included in each 
synthetic gene to facilitate cloning into the chloroplast expression vectors pASapI (atpA 
promoter/5’UTR used to drive GOI expression) and pSRSapI (psaA exon 1 promoter/5’UTR) as 
described in Wannathong et al. (2016). Plasmids were prepared from E. coli DH5α by alkaline 
lysis (Sambrook and Russell, 2001) and checked by SphI digestion and by Sanger DNA 
sequencing (Wolfson Institute for Biomedical Research, University College London). For algal 
transformation, larger plasmid preparations were made using a QIAfilter Plasmid Midi kit 
(Qiagen). 
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Transformation of C. reinhardtii   
The endolysin genes were introduced into the psbH–trnE2 intergenic region of the chloroplast 
genome of TN72 by homologous recombination, restoring a functional psbH gene and the ability 
to grow photosynthetically. The transformation procedure was based on that described by 
Kindle (1990). Cells were grown to mid-log phase (1–2 x 106 cells/ml) in TAP medium, 
harvested by centrifugation (8000 g, 8 min) and resuspended in TAP medium to 2 x 108 
cells/ml. The cell suspension (300 µl per transformation) was vortexed for 15 sec together with 
0.3 g of glass beads (Sigma-Aldrich, diameter 0.4-0.6 mm) and 2–20 µg of circular plasmid DNA. 
Molten top agar (3.5 ml HSM + 0.5% agar) at 42 ºC was mixed with the cell suspensions and 
poured onto HSM plates. The plates were incubated for 1 h in the dark, followed by 3–4 weeks 
at 20 ºC under 50 µmol/m2/s light. To confirm gene insertion and homoplasmicity of 
transformants, DNA was extracted using the Chelex 100 method as described by Werner and 
Mergenhagen (1998), and 2 µl of the DNA extract used in PCR reactions with the primers F1, R1 
and R3 (Young and Purton 2014). 
 
Southern blot analysis 
Genomic DNA (4 µg) of the recipient strain TN72, TN72_pal and TN72_cpl-1 was cut with the 
restriction enzymes SphI and EcoRI and separated on an agarose gel (1% w/v). The DNA was 
tranferred to a Hybond N (Amersham Biosciences) membrane as described in Sambrook and 
Russell (2001). Subsequently, the blot was hybridized with DNA probes (produced either by 
PCR or the digest of a plasmid) that bind within the pal and cpl-1 genes, as well as a probe that 
binds just before the insertion site of the expression cassette in all strains. DNA labelling and 
detection was performed with the DIG High Prime DNA Labelling and Detection Starter Kit II 
(Roche Diagnostics GmbH) according to the manufacturer’s instructions. 
 
SDS-PAGE and western blot analysis 
SDS-PAGE was carried out using the Mini-PROTEAN Tetra cell system (Bio-Rad) and gels based 
on the recipe by Laemmli (1970) containing 15% acrylamide. Samples were supplemented with 
sample loading buffer, boiled at 99 ºC for 3 min and centrifuged at 21 000 g for 2 min. The gels 
were run at 120–150V for 90–120 min. To visualize all proteins the gels were stained with 
Coomassie Brilliant Blue R solution for 1 h and destained for at least 2 h. The stained gels were 
scanned using the Odyssey® imaging system from LI-COR. 
For western blot analyses, the proteins were transferred to Hybond-ECL nitrocellulose 
membranes (GE Healthcare), at 19 V for 1 h using a Trans-Blot SD semi-dry electrophoretic 
transfer cell (Bio-Rad). The membranes were blocked overnight in TBS-T (TBS + 0.1% Tween) 
with 0.5% milk and incubated with the primary antibody (α-HA antibody from rabbit (Sigma-
Aldrich product H6908) diluted 1:2000 or anti-Pal antibodies (see below)) for 1–3 h followed 
by incubation with the secondary antibody for 1 h. Both antibodies were resuspended in TBS-T 
+ 0.5% milk, and the membranes were washed after each incubation 3x in TBS-T for 5–10 min. 
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When ECL IgG horseradish peroxidase-linked secondary antibodies (GE Healthcare, 1:10 000) 
were used, the membranes were incubated with SuperSignal® West Pico Chemiluminescence 
Substrate (Thermo Scientific) for 5 min and exposed to Hyperfilm ECL (GE Healthcare). For 
quantitative western blot analyses, IRDye® secondary antibodies (DylightTM 800, Thermo 
Scientific, 1:20 000) and the Odyssey® Infrared Imaging system (Li-COR Biosciences) were used. 
Custom made anti-Pal antibodies were raised by Eurogentec (Belgium) using two peptides of 17 
amino acids (see Figure S2) attached to keyhole limpet hemocyanin carrier protein. 
 
Preparation of C. reinhardtii extract 
C. reinhardtii cultures were grown to an OD750 of 2 to 3, harvested by centrifugation at 8000 g 
for 10 min and resuspended in 20 mM sodium phosphate (Na-Pi) buffer (pH 6.9) + protease 
inhibitor (Roche cOmplete, EDTA-free). Cells were either broken by three cycles of freezing and 
thawing (liquid nitrogen, 30 ºC) or sonication with the Cup Horn (Qsonica, LLC), followed by 
centrifugation at 21 000 g for 5 min (= crude extract).  
 
Endolysin isolation and quantification 
After cell breakage, cell suspensions were centrifuged at 5000 g for 20 min, followed by 
ultracentrifugation at 100 000 g for 1 h. Ultracentrifugation extracts were applied to a 
diethylethanolamine (DEAE) cellulose column. The column was washed with 6 column volumes 
(CV) of Na-Pi, 8 CV of Na-Pi + 1.5M NaCl and 4 CV of Na-Pi + 0.1M NaCl. Pal and Cpl-1 were 
eluted with 2 CV of Na-Pi + 0.1M NaCl + 6.5% (w/v) choline. The elution fractions with the 
highest amount of Pal and Cpl-1 were determined in protein microarrays (2 µl spots on 
nitrocellulose membranes, followed by western blot analysis protocol), combined and dialyzed 
using Slide-A-Lyzer G2 dialysis cassettes (20 000 MWCO) (Thermo Scientific). After dialysis, the 
elution was concentrated 10-fold by ammonium sulphate (AS) precipitation: Pal was 
precipitated with 35% AS, and Cpl-1 with 50% AS. Alternatively, the chromatography as 
described above was performed with an ÄKTA pure system (GE Healthcare Life Sciences) and 
the fractions with the highest amount of endolysin were concentrated with centrifugal 
concentrators (5 000 MWCO). Protein concentrations were determined using Bradford reagent 
(Sigma-Aldrich) and bovine serum albumin as standard (taking impurities into account).  
Endolysin concentration within C. reinhardtii lines TN72_pal and TN72_cpl-1 were quantified 
using serial dilutions of the isolated Pal or Cpl-1 in western blot analyses with anti-HA 
antibodies and IRDye® secondary antibodies. The IR fluorescence signals of the serial dilutions 
were plotted against the protein concentration (determined by Bradford assay, taking 
impurities into account) and the equations of the resulting trend lines were used to calculate the 
amount of Pal/Cpl-1 in cell lysates. The amount of total soluble protein (TSP) in the cell 
suspensions was determined by Bradford assay after cell breakage and centrifugation at 13 000 
g for 15 min (Manuell et al. 2007). The cell dry weight was determined after lyophilisation of the 
cell suspensions for 16h. 
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Assays of endolysin activity 
S. pneumoniae cultures were grown to mid-log phase, (S. pyogenes, E. coli and S. aureus 
overnight) harvested and resuspended in 20 mM Na-Pi. Most TRAs were performed at 37 ºC in 
96-well microtitre plates with 20 µl of crude extract in a final volume of 200 µl using a FLUOstar 
OPTIMA Microplate Reader (BMG Labtech Ltd) recording the OD595 over times courses of 60–
180 min. The assays in figure 7B and S10 were performed in cuvettes with 50 µl of crude extract 
in a final volume of 1 ml at room temperature. For the preparation of the crude extracts used in 
the TRAs, cultures of TN72_pal, TN72_cpl-1 and TN72_control were grown to the same OD750, 
harvested by centrifugation and resuspended in 1/100 of the culture volume. After cell 
breakage, the suspension was centrifuged at 21 000 g for 5 min and the supernatant was used 
as crude extract in the TRAs.  
To determine the colony forming units (cfu) that survived the endolysin treatment, samples 
from TRAs with the isolated endolysins were diluted in serial 10-fold dilutions and spotted in 
triplicate onto Columbia blood agar plates. After incubation overnight the cfu were counted and 
the decrease in cfu/ml calculated relative to an untreated control. For the cfu assays with S. 
pneumoniae D39, frozen aliquots (–80ºC) from an overnight culture were thawed and incubated 
with isolated endolysin at 37ºC for up to 200 min. The decrease in cfu was determined as 
described above.  
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Tables 
Table 1. Quantification of Pal and Cpl-1 accumulation in C. reinhardtii 
 
% of total soluble 
protein (TSP) 
mg endolysin / 
g of cell dry weight 
mg endolysin / 
L culture volume 
Pal 0.9 – 1.2 % 1.3 ± 0.4 
1.2 ± 0.4 
(Culture OD750nm of 3.8) 
Cpl-1 1.1 – 1.2 % 1.2 ± 0.7 
0.9 ± 0.3 
(Culture OD750nm of 3.0) 
 
Figure legends  
Figure 1. Schematic diagram of the transformation system used for the introduction of cpl-1 or 
pal into the chloroplast genome. (a) Homologous recombination (grey crosses) between 
chloroplast sequences (thick black lines) on the transformation vector pSRSapI and the genome 
of the recipient strain TN72 allows the introduction of the gene (under the control of the psaA-
exon 1 promoter/5’UTR and rbcL 3’ UTR from C. reinhardtii) into a neutral locus between psbH 
and trnE2. Recombination also replaces the aadA-disrupted copy of psbH with a functional copy 
of this essential photosystem II gene, allowing transformants to be selected by restoration of 
phototrophic growth (Wannathong et al. 2016). (b) PCR screening of putative transformants for 
correct insertion of cpl-1, pal(HA-) and pal and homoplasmicity of the polyploidy chloroplast 
genome using a set of three primers. Primer F1 (black triangle in (a)) binds to the genome 
outside of the recombination region. Primer R1 (grey triangle) binds within the aadA cassette of 
TN72 and results together with primer F1 in a product of 0.88 kb. Primer R3 (white triangle) 
binds within the gene cassette of the transformants and results together with primer F1 in a 
product of 1.13 kb. Homoplasmy is scored by a band at 1.13 kb and an absence of a 0.88 kb band 
arising from untransformed copies of the plastome (Wannathong et al. 2016). 
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Figure 2. Western blot analysis of endolysin accumulation in transgenic lines. (a) Detection of 
HA-tagged Cpl-1 and HA-tagged Pal in equivalent loadings of cell extracts from two 
representative transgenic lines (TN72_cpl1 and TN72_pal) using anti-HA antibodies, together 
with the negative control transformant (TN72_control). (b) Comparison of levels of untagged 
Pal and HA-tagged Pal in extracts from two representative lines (TN72_pal(HA-) using custom 
made anti-Pal antibodies. Binding of the different primary antibodies to non-specific (n.s.) 
bands within the extracts serves as loading controls. 
 
Figure 3. Stability of Pal after inhibition of chloroplast protein synthesis by chloramphenicol. 
Cultures of TN72_pal were grown under standard conditions to an OD750nm of 1 before treating 
half with 500 μg/ml chloramphenicol and incubating for a further 122 h. The experiment was 
performed both in the light and the dark with samples taken at different time points. Samples 
were normalized to the same cell density and analysed by western blotting using anti-HA and 
anti-D1 antibodies. + = Chloramphenicol treated cultures, – = untreated controls.  
 
Figure 4. SDS-PAGE analysis of isolated Pal and Cpl-1. The recombinant proteins were isolated 
from the crude cell lysate following ultracentrifugation (= UC sup.) using diethylaminoethanol 
(DEAE) cellulose with choline as the specific eluent. The elution fractions with the highest 
amount of Pal and Cpl-1 were pooled (= Elu.) and concentrated using ammonium sulphate 
precipitation (= Elu. conc.). The figure shows Coomassie stained gels recorded using the 
Odyssey® Infrared Imaging system. 
 
Figure 5. Quantification of Pal and Cpl-1 accumulation in C. reinhardtii. (a) Cell lysates of 
TN72_pal and TN72_cpl-1 were compared to a dilution series of known amounts of isolated Pal 
or Cpl-1 in western blot analysis using anti-HA antibodies and IRDye® secondary antibodies. 
The amount of total soluble protein (TSP) in the cell lysates is stated above each lane. For each 
strain, ‘Culture 1’ was grown to an OD750 of 2.5 and ‘Culture 2’ to an OD750 of 3.0. The cultures 
were concentrated 5 times (lane 1) or 2.5 times (lane 2) in comparison to the initial culture 
volume before preparation of the cell lysates. (b) The IR fluorescence signals of the serial 
dilutions were plotted against the protein concentration of the isolated endolysin preparations 
(taking impurities in the isolated proteins into account) and the equations of the resulting trend 
lines used to calculate the concentration of Pal/Cpl-1 in the cell lysates. 
 
Figure 6. Turbidity reduction assay showing the lytic activity of crude cell extracts containing 
Pal (HA-tagged and untagged) and Cpl-1. Streptococcus pneumoniae (16 NP3, serotype 19F) cells 
were resuspended in Na-Pi buffer to an OD595 of 0.1. Crude extracts of equal concentration of 
TN72_pal, TN72_pal(HA-), TN72_cpl-1 and TN72_control were added to the S. pneumoniae 
suspension and the cell lysis was measured as decrease in OD595. Lysis of the bacterium by 
0.05% deoxycholate was used as a positive control. Error bars show ± one standard deviation (n 
= 2). 
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Figure 7. Lytic activity of Pal and Cpl-1 against clinical isolates of S. pneumoniae and specificity 
of Pal for S. pneumoniae. (a) Suspensions of clinical isolates with an initial OD595 of 0.5, (0.15 for 
ST4157) were treated with crude extracts of equal concentration of TN72_pal, TN72_cpl-1 or 
TN72_control. (b) TN72_pal and TN72_control extracts were added to cultures of S. pneumoniae 
(16 NP3, serotype 19F), Escherichia coli, Staphylococcus aureus and Streptococcus pyogenes 
(initial OD600 0.8–1.0). The graphs show the decrease in OD per minute (divided by 0.001) in the 
linear range with changes in the OD of the corresponding control subtracted from the results. 
ST65 = serotype 6A, ST176 = serotype 6B, ST1390 = serotype 6C, ST4157 = serotype 6B, 35 NP1. 
The error bars show ± one standard deviation ((a) n = 3, (b) n = 2)).  
Figure 8. In vitro killing of S. pneumoniae by isolated Pal and Cpl-1. (a) S. pneumoniae 16 NP3 or 
(b) D39 was incubated with isolated Pal, Cpl-1 or deoxycholate as a positive control. In (b) 45 
µg/ml of Pal killed all S pneumoniae D39 cells and reduced therefore the cfu/ml by more than 
7.5 log10 units. The graph shows the decrease in bacterial titres in powers of 10 in comparison 
to an untreated control. The error bars show ± one standard deviation (n = 3). 
 
Supporting information 
Additional supporting information may be found in the online version of this article:  
Figure S1. The pal and cpl-1 sequences codon-optimised for the C. reinhardtii chloroplast. 
Figure S2. Southern blot analysis confirming the predicted insertion of pal and cpl-1 into the 
plastome of TN72. 
Figure S3. Protein sequence of Pal showing the peptide sequences used to raise antibodies. 
Figure S4. Growth of C. reinhardtii TN72_pal compared to the TN72_control. 
Figure S5. Comparison of the amount of Pal produced using the atpA or psaA exon 1 
promoter/5’UTR elements. 
Figure S6. Comparison of the amount of Cpl-1 produced using the atpA or psaA exon 1 
promoter/5’UTR elements. 
Figure S7. Yield of Pal at different growth stages and the influence of darkness on the protein 
stability during stationary phase. 
Figure S8. Yield of Pal per culture volume at different growth stages during mixotrophic and 
heterotrophic growth. 
Figure S9. Turbidity reduction assay showing the lytic activity of crude cell extracts containing Pal 
and Cpl-1 against clinical isolates of S. pneumoniae. 
Figure S10. Turbidity reduction assays showing the specific lytic activity of Pal produced in C. 
reinhardtii against Streptococcus pneumoniae compared to Escherichia coli, Streptococcus pyogenes 
and Staphylococcus aureus.  
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Figure 1. Schematic diagram of the transformation system used for the introduction of cpl-1 or 
pal into the chloroplast genome. (a) Homologous recombination (grey crosses) between 
chloroplast sequences (thick black lines) on the transformation vector pSRSapI and the genome 
of the recipient strain TN72 allows the introduction of the gene (under the control of the psaA-
exon 1 promoter/5’UTR and rbcL 3’ UTR from C. reinhardtii) into a neutral locus between psbH 
and trnE2. Recombination also replaces the aadA-disrupted copy of psbH with a functional copy 
of this essential photosystem II gene, allowing transformants to be selected by restoration of 
phototrophic growth (Wannathong et al. 2016). (b) PCR screening of putative transformants for 
correct insertion of cpl-1, pal(HA-) and pal and homoplasmicity of the polyploidy chloroplast 
genome using a set of three primers. Primer F1 (black triangle in (a)) binds to the genome 
outside of the recombination region. Primer R1 (grey triangle) binds within the aadA cassette of 
TN72 and results together with primer F1 in a product of 0.88 kb. Primer R3 (white triangle) 
binds within the gene cassette of the transformants and results together with primer F1 in a 
product of 1.13 kb. Homoplasmy is scored by a band at 1.13 kb and the absence of a 0.88 kb 
band arising from untransformed copies of the plastome (Wannathong et al. 2016). 
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Figure 2. Western blot analysis of endolysin accumulation in transgenic lines. (a) Detection of 
HA-tagged Cpl-1 and HA-tagged Pal in equivalent loadings of cell extracts from two 
representative transgenic lines (TN72_cpl-1 and TN72_pal) using anti-HA antibodies, together 
with the negative control transformant (TN72_control). (b) Comparison of levels of untagged 
Pal and HA-tagged Pal in extracts from two representative lines (TN72_pal(HA-) using custom 
made anti-Pal antibodies. Binding of the different primary antibodies to non-specific (n.s.) 
bands within the extracts serves as loading controls. 
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Figure 3. Stability of Pal after inhibition of chloroplast protein synthesis by chloramphenicol. 
Cultures of TN72_pal were grown under standard conditions to an OD750nm of 1 before treating 
half with 500 μg/ml chloramphenicol and incubating for a further 122 h. The experiment was 
performed both in the light and the dark with samples taken at different time points. Samples 
were normalized to the same cell density and analysed by western blotting using anti-HA and 
anti-D1 antibodies. + = Chloramphenicol treated cultures, – = untreated controls. 
 
 
 
Figure 4. SDS-PAGE analysis of isolated Pal and Cpl-1. The recombinant proteins were isolated 
from the crude cell lysate following ultracentrifugation (= UC sup.) using diethylaminoethanol 
(DEAE) cellulose with choline as the specific eluent. The elution fractions with the highest 
amount of Pal and Cpl-1 were pooled (= Elu.) and concentrated using ammonium sulphate 
precipitation (= Elu. conc.). The figure shows Coomassie stained gels recorded using the 
Odyssey® Infrared Imaging system.  
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Figure 5. Quantification of Pal and Cpl-1 accumulation in C. reinhardtii. (a) Cell lysates of 
TN72_pal and TN72_cpl-1 were compared to a dilution series of known amounts of isolated Pal 
or Cpl-1 in western blot analysis using anti-HA antibodies and IRDye® secondary antibodies. 
The amount of total soluble protein (TSP) in the cell lysates is stated above each lane. For each 
strain, ‘Culture 1’ was grown to an OD750 of 2.5 and ‘Culture 2’ to an OD750 of 3.0. The cultures 
were concentrated 5 times (lane 1) or 2.5 times (lane 2) in comparison to the initial culture 
volume before preparation of the cell lysates. (b) The IR fluorescence signals of the serial 
dilutions were plotted against the protein concentration of the isolated endolysin preparations 
(taking impurities in the isolated proteins into account) and the equations of the resulting trend 
lines used to calculate the concentration of Pal/Cpl-1 in the cell lysates. 
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Figure 6. Turbidity reduction assay showing the lytic activity of crude cell extracts containing 
Pal (HA-tagged and untagged) and Cpl-1. Streptococcus pneumoniae (16 NP3, serotype 19F) cells 
were resuspended in Na-Pi buffer to an OD595 of 0.1. Crude extracts of equal concentration of 
TN72_pal, TN72_pal(HA-), TN72_cpl-1 and TN72_control were added to the S. pneumoniae 
suspension and the cell lysis was measured as decrease in OD595. Lysis of the bacterium by 
0.05% deoxycholate was used as a positive control. Error bars show ± one standard deviation (n 
= 2). 
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Figure 7. Lytic activity of Pal and Cpl-1 against clinical isolates of S. pneumoniae and specificity 
of Pal for S. pneumoniae. (a) Suspensions of clinical isolates with an initial OD595 of 0.5, (0.15 for 
ST4157) were treated with crude extracts of equal concentration of TN72_pal, TN72_cpl-1 or 
TN72_control. (b) TN72_pal and TN72_control extracts were added to cultures of S. pneumoniae 
(16 NP3, serotype 19F), Escherichia coli, Staphylococcus aureus and Streptococcus pyogenes 
(initial OD600 0.8–1.0). The graphs show the decrease in OD per minute (divided by 0.001) in the 
linear range with changes in the OD of the corresponding control subtracted from the results. 
ST65 = serotype 6A, ST176 = serotype 6B, ST1390 = serotype 6C, ST4157 = serotype 6B, 35 NP1. 
The error bars show ± one standard deviation ((a) n = 3, (b) n = 2)).  
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Figure 8. In vitro killing of S. pneumoniae by isolated Pal and Cpl-1. (a) S. pneumoniae 16 NP3 or 
(b) D39 was incubated with isolated Pal, Cpl-1 or deoxycholate as a positive control. In (b) 45 
µg/ml of Pal killed all S pneumoniae D39 cells and therefore reduced the cfu/ml by more than 
7.5 log10 units. The graph shows the decrease in bacterial titres by powers of 10 in comparison 
to an untreated control. The error bars show ± one standard deviation (n = 3). 
 
 
